Rheumatoid arthritis: Strategies in the management of patients showing an inadequate response to TNFα antagonists

Joseph R. Lutt, Atulya (Atul) Deodhar

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The introduction of medications that target specific proinflammatory cytokines has revolutionized the management of patients with rheumatoid arthritis. The agents that antagonize the effects of tumour necrosis factor (TNF)-α - infliximab, etanercept and adalimumab - have consistently shown very good efficacy for controlling the clinical and radiographic manifestations of the disease. However, it has become apparent that some patients will receive no clinical benefit, gradually lose the effect over time or experience adverse effects with the TNFα antagonists. The management of these patients is challenging and there are no clear guidelines. The concomitant administration of a disease-modifying antirheumatic drug, such as methotrexate, has been shown to improve outcomes. Optimization of the methotrexate or TNFα antagonist dose may lead to improved responses, as demonstrated in some dose escalation studies. Switching to another TNFα antagonist is a step that is supported by small, mostly uncontrolled studies. Finally, the T-cell co-stimulation antagonist abatacept, as well as the B-cell depleting agent rituximab, are also available for use in patients who have had an inadequate response or intolerance to the TNFα antagonists. Genotypic studies have identified TNF and TNF receptor polymorphisms that appear to predict independently whether a patient will respond to a TNFα antagonist, but genotyping is not available for routine use in clinical practice. Until such tools for predicting response are widely available, the management of patients with poor responses to TNFα antagonists will have to depend upon the wishes of the patient regarding medication dosage schedules and adverse effect profiles, as well as how comfortable the treating physician is with the available biological medications. In this article, we review the current data and construct an algorithm to help guide clinicians in the management of patients with inadequate responses to the TNFα antagonists.

Original languageEnglish (US)
Pages (from-to)591-606
Number of pages16
JournalDrugs
Volume68
Issue number5
DOIs
StatePublished - 2008

Fingerprint

Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Methotrexate
Antirheumatic Agents
T-cells
Tumor Necrosis Factor Receptors
Polymorphism
Appointments and Schedules
B-Lymphocytes
Cells
Guidelines
Cytokines
Physicians
T-Lymphocytes

Keywords

  • Abatacept, therapeutic use
  • Rheumatoid arthritis, treatment
  • Rituximab, therapeutic use
  • Tumour necrosis factor alpha inhibitors, therapeutic use

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Rheumatoid arthritis : Strategies in the management of patients showing an inadequate response to TNFα antagonists. / Lutt, Joseph R.; Deodhar, Atulya (Atul).

In: Drugs, Vol. 68, No. 5, 2008, p. 591-606.

Research output: Contribution to journalArticle

@article{04a1ad1fdb8c4ae1b708c23a9a0ddd71,
title = "Rheumatoid arthritis: Strategies in the management of patients showing an inadequate response to TNFα antagonists",
abstract = "The introduction of medications that target specific proinflammatory cytokines has revolutionized the management of patients with rheumatoid arthritis. The agents that antagonize the effects of tumour necrosis factor (TNF)-α - infliximab, etanercept and adalimumab - have consistently shown very good efficacy for controlling the clinical and radiographic manifestations of the disease. However, it has become apparent that some patients will receive no clinical benefit, gradually lose the effect over time or experience adverse effects with the TNFα antagonists. The management of these patients is challenging and there are no clear guidelines. The concomitant administration of a disease-modifying antirheumatic drug, such as methotrexate, has been shown to improve outcomes. Optimization of the methotrexate or TNFα antagonist dose may lead to improved responses, as demonstrated in some dose escalation studies. Switching to another TNFα antagonist is a step that is supported by small, mostly uncontrolled studies. Finally, the T-cell co-stimulation antagonist abatacept, as well as the B-cell depleting agent rituximab, are also available for use in patients who have had an inadequate response or intolerance to the TNFα antagonists. Genotypic studies have identified TNF and TNF receptor polymorphisms that appear to predict independently whether a patient will respond to a TNFα antagonist, but genotyping is not available for routine use in clinical practice. Until such tools for predicting response are widely available, the management of patients with poor responses to TNFα antagonists will have to depend upon the wishes of the patient regarding medication dosage schedules and adverse effect profiles, as well as how comfortable the treating physician is with the available biological medications. In this article, we review the current data and construct an algorithm to help guide clinicians in the management of patients with inadequate responses to the TNFα antagonists.",
keywords = "Abatacept, therapeutic use, Rheumatoid arthritis, treatment, Rituximab, therapeutic use, Tumour necrosis factor alpha inhibitors, therapeutic use",
author = "Lutt, {Joseph R.} and Deodhar, {Atulya (Atul)}",
year = "2008",
doi = "10.2165/00003495-200868050-00003",
language = "English (US)",
volume = "68",
pages = "591--606",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Rheumatoid arthritis

T2 - Strategies in the management of patients showing an inadequate response to TNFα antagonists

AU - Lutt, Joseph R.

AU - Deodhar, Atulya (Atul)

PY - 2008

Y1 - 2008

N2 - The introduction of medications that target specific proinflammatory cytokines has revolutionized the management of patients with rheumatoid arthritis. The agents that antagonize the effects of tumour necrosis factor (TNF)-α - infliximab, etanercept and adalimumab - have consistently shown very good efficacy for controlling the clinical and radiographic manifestations of the disease. However, it has become apparent that some patients will receive no clinical benefit, gradually lose the effect over time or experience adverse effects with the TNFα antagonists. The management of these patients is challenging and there are no clear guidelines. The concomitant administration of a disease-modifying antirheumatic drug, such as methotrexate, has been shown to improve outcomes. Optimization of the methotrexate or TNFα antagonist dose may lead to improved responses, as demonstrated in some dose escalation studies. Switching to another TNFα antagonist is a step that is supported by small, mostly uncontrolled studies. Finally, the T-cell co-stimulation antagonist abatacept, as well as the B-cell depleting agent rituximab, are also available for use in patients who have had an inadequate response or intolerance to the TNFα antagonists. Genotypic studies have identified TNF and TNF receptor polymorphisms that appear to predict independently whether a patient will respond to a TNFα antagonist, but genotyping is not available for routine use in clinical practice. Until such tools for predicting response are widely available, the management of patients with poor responses to TNFα antagonists will have to depend upon the wishes of the patient regarding medication dosage schedules and adverse effect profiles, as well as how comfortable the treating physician is with the available biological medications. In this article, we review the current data and construct an algorithm to help guide clinicians in the management of patients with inadequate responses to the TNFα antagonists.

AB - The introduction of medications that target specific proinflammatory cytokines has revolutionized the management of patients with rheumatoid arthritis. The agents that antagonize the effects of tumour necrosis factor (TNF)-α - infliximab, etanercept and adalimumab - have consistently shown very good efficacy for controlling the clinical and radiographic manifestations of the disease. However, it has become apparent that some patients will receive no clinical benefit, gradually lose the effect over time or experience adverse effects with the TNFα antagonists. The management of these patients is challenging and there are no clear guidelines. The concomitant administration of a disease-modifying antirheumatic drug, such as methotrexate, has been shown to improve outcomes. Optimization of the methotrexate or TNFα antagonist dose may lead to improved responses, as demonstrated in some dose escalation studies. Switching to another TNFα antagonist is a step that is supported by small, mostly uncontrolled studies. Finally, the T-cell co-stimulation antagonist abatacept, as well as the B-cell depleting agent rituximab, are also available for use in patients who have had an inadequate response or intolerance to the TNFα antagonists. Genotypic studies have identified TNF and TNF receptor polymorphisms that appear to predict independently whether a patient will respond to a TNFα antagonist, but genotyping is not available for routine use in clinical practice. Until such tools for predicting response are widely available, the management of patients with poor responses to TNFα antagonists will have to depend upon the wishes of the patient regarding medication dosage schedules and adverse effect profiles, as well as how comfortable the treating physician is with the available biological medications. In this article, we review the current data and construct an algorithm to help guide clinicians in the management of patients with inadequate responses to the TNFα antagonists.

KW - Abatacept, therapeutic use

KW - Rheumatoid arthritis, treatment

KW - Rituximab, therapeutic use

KW - Tumour necrosis factor alpha inhibitors, therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=41349113569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41349113569&partnerID=8YFLogxK

U2 - 10.2165/00003495-200868050-00003

DO - 10.2165/00003495-200868050-00003

M3 - Article

C2 - 18370440

AN - SCOPUS:41349113569

VL - 68

SP - 591

EP - 606

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 5

ER -